Your browser is no longer supported. Please, upgrade your browser.
Settings
OYST Oyster Point Pharma, Inc. daily Stock Chart
OYST [NASD]
Oyster Point Pharma, Inc.
Index- P/E- EPS (ttm)-2.89 Insider Own1.30% Shs Outstand23.44M Perf Week12.83%
Market Cap639.58M Forward P/E- EPS next Y-3.68 Insider Trans0.00% Shs Float22.05M Perf Month-5.47%
Income-63.20M PEG- EPS next Q-0.67 Inst Own84.50% Short Float2.89% Perf Quarter-25.37%
Sales- P/S- EPS this Y-167.20% Inst Trans6.93% Short Ratio4.69 Perf Half Y-21.52%
Book/sh9.42 P/B2.68 EPS next Y-36.80% ROA-43.20% Target Price- Perf Year-
Cash/sh8.95 P/C2.82 EPS next 5Y- ROE-60.50% 52W Range13.26 - 41.37 Perf YTD3.27%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-36.67% Beta-
Dividend %- Quick Ratio26.30 Sales past 5Y- Gross Margin- 52W Low97.59% ATR1.68
Employees30 Current Ratio26.30 Sales Q/Q- Oper. Margin- RSI (14)53.98 Volatility9.08% 6.64%
OptionableNo Debt/Eq0.00 EPS Q/Q-26.80% Profit Margin- Rel Volume0.32 Prev Close25.24
ShortableYes LT Debt/Eq0.00 EarningsAug 05 BMO Payout- Avg Volume136.09K Price26.20
Recom2.00 SMA206.44% SMA50-3.94% SMA200-4.53% Volume15,071 Change3.80%
Nov-25-19Initiated Piper Jaffray Overweight $35
Nov-25-19Initiated JP Morgan Overweight $26
Nov-25-19Initiated Cowen Outperform $40
Aug-05-20 07:00AM  
Jul-31-20 04:01PM  
Jun-01-20 11:39AM  
May-28-20 09:07AM  
May-24-20 12:25PM  
May-19-20 06:08PM  
May-15-20 02:02AM  
May-12-20 04:20PM  
May-11-20 10:31PM  
06:05AM  
06:00AM  
May-04-20 04:05PM  
Mar-30-20 07:30AM  
Feb-27-20 04:01PM  
Feb-24-20 08:00AM  
08:00AM  
Jan-12-20 08:00PM  
Dec-24-19 07:24AM  
Dec-23-19 09:00AM  
Dec-17-19 08:00AM  
Dec-03-19 03:29PM  
07:00AM  
Nov-25-19 08:00AM  
Nov-22-19 05:12PM  
Nov-05-19 09:10AM  
Oct-28-19 08:20AM  
Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company's lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that is in Phase III clinical trials for the treatment of signs and symptoms of dry eye disease. It is also developing OC-01 for neurotrophic keratitis. Oyster Point Pharma, Inc. was founded in 2015 and is headquartered in Princeton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nau JeffreyPresident and CEOJul 28Option Exercise1.025,0005,1005,000Jul 30 07:37 PM